CSIMarket



Worst Performing Stocks In Healthcare Sector During This Current Quarter Q2 Of 2024



 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 
 

Shares are down by -2.4% on average, in Healthcare Sector during this current quarter q2 of 2024.

Here are the Worst performing stocks in Healthcare Sector.




BTTX

$0.0081

$-0.2069 -96.23%
This Quarter Q2 of 2024


BTTX

$0.0081

$-0.2069 -96.23%



Better Therapeutics Inc

Better Therapeutics Inc shares went down -96.23% during this current quarter q2 of 2024.


Better Therapeutics Inc is a digital therapeutics company that combines evidenced-based clinical interventions with software technology to address chronic diseases. Their business model revolves around developing and delivering prescription software applications to patients, which are meant to be used alongside pharmaceutical therapies. Their aim is to provide personalized and scalable solutions that have the potential to improve health outcomes and reduce healthcare costs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.312 mill. $ - mill. $ -31.573 mill. 39 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.312 mill.


$ - mill.


$ -31.573 mill.

Employees Shares Outstanding P/E

-


39 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ALLR

$0.4678

$-7.5502 -94.17%
This Quarter Q2 of 2024


ALLR

$0.4678

$-7.5502 -94.17%



Allarity Therapeutics Inc

Allarity Therapeutics Inc stock declined -94.17% during this current quarter q2 of 2024.


Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.058 mill. $ - mill. $ -20.698 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.058 mill.


$ - mill.


$ -20.698 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



LYRA

$0.3101

$-4.9999 -94.16%
This Quarter Q2 of 2024


LYRA

$0.3101

$-4.9999 -94.16%



Lyra Therapeutics Inc

Lyra Therapeutics Inc shares declined -94.16% during this current quarter q2 of 2024.


Lyra Therapeutics Inc is a biotechnology company that focuses on developing drug-delivery systems for patients with ear, nose, and throat (ENT) diseases. They utilize their proprietary technology, known as XTreo, to precisely deliver therapeutics to targeted areas within the ENT region. Their business model revolves around developing and commercializing these unique drug-delivery solutions to address unmet medical needs in the ENT field.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 17.661 mill. $ 1.423 mill. $ -61.759 mill. 57 mill. - Y/Y 51.53 %
Market Cap. Revenues TTM Net Income TTM

$ 17.661 mill.


$ 1.423 mill.


$ -61.759 mill.

Employees Shares Outstanding P/E

-


57 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 51.53 %


MRQ Y/Y - %



SBFM

$0.3929

$-5.4371 -93.26%
This Quarter Q2 of 2024


SBFM

$0.3929

$-5.4371 -93.26%



Sunshine Biopharma Inc

Sunshine Biopharma Inc stock went down -93.26% during this current quarter q2 of 2024.


Sunshine Biopharma Inc is a pharmaceutical company that focuses on developing and commercializing drugs for the treatment of cancer and other diseases. They utilize their expertise in drug discovery and development to create innovative treatments that target specific molecular targets in order to deliver more effective and personalized therapies for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.003 mill. $ 26.740 mill. $ -4.087 mill. 0 mill. - Y/Y 54.09 %
Market Cap. Revenues TTM Net Income TTM

$ 0.003 mill.


$ 26.740 mill.


$ -4.087 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 54.09 %


MRQ Y/Y - %



AMPE

$0.13

$-1.4950 -92.00%
This Quarter Q2 of 2024


AMPE

$0.13

$-1.4950 -92.00%



Ampio Pharmaceuticals inc

Ampio Pharmaceuticals Inc shares declined -92.00% during this current quarter q2 of 2024.


Ampio Pharmaceuticals Inc is a biopharmaceutical company primarily focused on the development of therapies for debilitating diseases. Their business model revolves around identifying unmet medical needs and developing innovative drug candidates to address these needs. They aim to create value through successful clinical development and commercialization of their products, ultimately benefiting patients and generating revenue for the company.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.105 mill. $ - mill. $ -8.632 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.105 mill.


$ - mill.


$ -8.632 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VINC

$0.6889

$-7.2311 -91.30%
This Quarter Q2 of 2024


VINC

$0.6889

$-7.2311 -91.30%



Vincerx Pharma Inc

Vincerx Pharma Inc stock declined -91.30% during this current quarter q2 of 2024.


Vincerx Pharma Inc*s business model is focused on developing and commercializing novel small molecule drugs for the treatment of cancer. They aim to leverage their scientific expertise and collaborations to identify and advance promising drug candidates, ultimately providing innovative therapies to patients in need.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 14.742 mill. $ - mill. $ -38.245 mill. 21 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 14.742 mill.


$ - mill.


$ -38.245 mill.

Employees Shares Outstanding P/E

-


21 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



NDRA

$0.101

$-1.0490 -91.22%
This Quarter Q2 of 2024


NDRA

$0.101

$-1.0490 -91.22%



Endra Life Sciences Inc

Endra Life Sciences Inc stock declined -91.22% during this current quarter q2 of 2024.


Endra Life Sciences Inc*s business model focuses on developing and commercializing advanced imaging technologies and solutions for medical and industrial applications.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.091 mill. $ - mill. $ -9.893 mill. 11 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.091 mill.


$ - mill.


$ -9.893 mill.

Employees Shares Outstanding P/E

-


11 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GLYC

$0.2705

$-2.4595 -90.09%
This Quarter Q2 of 2024


GLYC

$0.2705

$-2.4595 -90.09%



Glycomimetics Inc

Glycomimetics Inc stock went down -90.09% during this current quarter q2 of 2024.


Glycomimetics Inc is a biopharmaceutical company that utilizes its expertise in carbohydrate chemistry to develop novel drug candidates. Their business model involves researching and developing proprietary glycomimetic compounds that can target specific disease pathways. They then collaborate with pharmaceutical partners to further develop and commercialize these potential therapeutics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 17.436 mill. $ - mill. $ 0.000 mill. 64 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 17.436 mill.


$ - mill.


$ 0.000 mill.

Employees Shares Outstanding P/E

-


64 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



EFTR

$1.37

$-11.7900 -89.59%
This Quarter Q2 of 2024


EFTR

$1.37

$-11.7900 -89.59%



Effector Therapeutics Inc

Effector Therapeutics Inc stock declined -89.59% during this current quarter q2 of 2024.


Effector Therapeutics Inc is a biotech company focused on developing and commercializing effective cancer treatments.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.385 mill. $ - mill. $ -35.941 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 3.385 mill.


$ - mill.


$ -35.941 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MBIO

$0.1354

$-1.1146 -89.17%
This Quarter Q2 of 2024


MBIO

$0.1354

$-1.1146 -89.17%



Mustang Bio inc

Mustang Bio Inc shares dropped -89.17% during this current quarter q2 of 2024.


Mustang Bio Inc operates on a business model focused on developing advanced therapies for challenging diseases. They primarily engage in research, development, and commercialization of innovative gene and cell therapies. Mustang Bio Inc aims to provide cutting-edge treatments to patients in need by leveraging its expertise in gene editing technologies and strategic partnerships.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.106 mill. $ - mill. $ -70.209 mill. 8 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.106 mill.


$ - mill.


$ -70.209 mill.

Employees Shares Outstanding P/E

330


8 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MOTS

$0.0694

$-0.5600 -88.97%
This Quarter Q2 of 2024


MOTS

$0.0694

$-0.5600 -88.97%



Motus Gi Holdings Inc

Motus Gi Holdings Inc stock went down -88.97% during this current quarter q2 of 2024.


Motus Gi Holdings Inc operates as a medical technology company that designs, develops, and commercializes innovative solutions for gastrointestinal endoscopy procedures. Their business model is centered around providing healthcare professionals with advanced imaging and therapeutic technologies to improve patient outcomes and enhance procedural efficiency.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.598 mill. $ -441.767 mill. $ -1.891 mill. 9 mill. - Y/Y -41.28 %
Market Cap. Revenues TTM Net Income TTM

$ 0.598 mill.


$ -441.767 mill.


$ -1.891 mill.

Employees Shares Outstanding P/E

-


9 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -41.28 %


MRQ Y/Y - %



AEON

$1.36

$-9.9000 -87.92%
This Quarter Q2 of 2024


AEON

$1.36

$-9.9000 -87.92%



Aeon Biopharma inc

Aeon Biopharma Inc stock went down -87.92% during this current quarter q2 of 2024.


Aeon Biopharma Inc.*s business model focuses on the development and commercialization of biopharmaceutical products, emphasizing innovation and collaboration for the advancement of healthcare.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 83.466 mill. $ - mill. $ 4.825 mill. 61 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 83.466 mill.


$ - mill.


$ 4.825 mill.

Employees Shares Outstanding P/E

-


61 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y 451.84 %



SPRB

$0.6721

$-4.4379 -86.85%
This Quarter Q2 of 2024


SPRB

$0.6721

$-4.4379 -86.85%



Spruce Biosciences Inc

Spruce Biosciences Inc stock dropped -86.85% during this current quarter q2 of 2024.


Spruce Biosciences Inc*s business model focuses on developing and commercializing novel therapies for rare endocrine disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 27.362 mill. $ 7.202 mill. $ -49.114 mill. 41 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 27.362 mill.


$ 7.202 mill.


$ -49.114 mill.

Employees Shares Outstanding P/E

-


41 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VAXX

$0.1

$-0.5956 -85.62%
This Quarter Q2 of 2024


VAXX

$0.1

$-0.5956 -85.62%



Vaxxinity Inc

Vaxxinity Inc stock dropped -85.62% during this current quarter q2 of 2024.


Vaxxinity Inc is a company that operates on a business model that focuses on the development and distribution of vaccines.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 12.652 mill. $ - mill. $ -56.934 mill. 127 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 12.652 mill.


$ - mill.


$ -56.934 mill.

Employees Shares Outstanding P/E

-


127 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



APVO

$0.781

$-4.4090 -84.95%
This Quarter Q2 of 2024


APVO

$0.781

$-4.4090 -84.95%



Aptevo Therapeutics Inc

Aptevo Therapeutics Inc shares declined -84.95% during this current quarter q2 of 2024.


Aptevo Therapeutics Inc operates as a biotechnology company that focuses on the development of novel oncology and hematology therapeutics. The company primarily generates revenue through the sale of its products and potential collaborations with other pharmaceutical companies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.223 mill. $ - mill. $ -16.151 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.223 mill.


$ - mill.


$ -16.151 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VRPX

$0.7037

$-3.8263 -84.47%
This Quarter Q2 of 2024


VRPX

$0.7037

$-3.8263 -84.47%



Virpax Pharmaceuticals Inc

Virpax Pharmaceuticals Inc stock declined -84.47% during this current quarter q2 of 2024.


Virpax Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing innovative non-opioid products to address the unmet needs in pain management. Their business model revolves around research, development, and commercialization of these non-opioid solutions to provide effective and safe pain relief options for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.824 mill. $ - mill. $ -13.615 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.824 mill.


$ - mill.


$ -13.615 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MRNS

$1.46

$-7.3900 -83.50%
This Quarter Q2 of 2024


MRNS

$1.46

$-7.3900 -83.50%



Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals Inc shares dropped -83.50% during this current quarter q2 of 2024.


Marinus Pharmaceuticals Inc operates on a business model centered around developing and commercializing innovative therapeutics for rare neurological disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 83.004 mill. $ 31.478 mill. $ -138.305 mill. 57 mill. - Y/Y 7.22 %
Market Cap. Revenues TTM Net Income TTM

$ 83.004 mill.


$ 31.478 mill.


$ -138.305 mill.

Employees Shares Outstanding P/E

-


57 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 7.22 %


MRQ Y/Y - %



CNSP

$3.62

$-17.8750 -83.16%
This Quarter Q2 of 2024


CNSP

$3.62

$-17.8750 -83.16%



Cns Pharmaceuticals Inc

Cns Pharmaceuticals Inc stock went down -83.16% during this current quarter q2 of 2024.


CNS Pharmaceuticals Inc*s business model focuses on developing innovative solutions and treatments for central nervous system diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 31.540 mill. $ 0.034 mill. $ -17.464 mill. 9 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 31.540 mill.


$ 0.034 mill.


$ -17.464 mill.

Employees Shares Outstanding P/E

-


9 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



HSDT

$1.06

$-4.8600 -82.09%
This Quarter Q2 of 2024


HSDT

$1.06

$-4.8600 -82.09%



Helius Medical Technologies inc

Helius Medical Technologies Inc stock declined -82.09% during this current quarter q2 of 2024.


Helius Medical Technologies Inc is a company that operates on a subscription-based business model, providing medical technology solutions for the treatment of neurological symptoms and conditions through its proprietary platform known as PoNS. This includes offering PoNS devices and related therapy services to healthcare providers and patients, with an aim to improve patient outcomes and quality of life.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.866 mill. $ 0.668 mill. $ -8.872 mill. 1 mill. - Y/Y 21.62 %
Market Cap. Revenues TTM Net Income TTM

$ 0.866 mill.


$ 0.668 mill.


$ -8.872 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 21.62 %


MRQ Y/Y - %



SINT

$4.73

$-21.6700 -82.08%
This Quarter Q2 of 2024


SINT

$4.73

$-21.6700 -82.08%



Sintx Technologies Inc

Sintx Technologies Inc stock dropped -82.08% during this current quarter q2 of 2024.


Sintx Technologies Inc is a company that operates under a business model focused on developing and commercializing silicon nitride-based ceramics for various applications.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 163.000 mill. $ 2.775 mill. $ -8.852 mill. 34 mill. - Y/Y 27.46 %
Market Cap. Revenues TTM Net Income TTM

$ 163.000 mill.


$ 2.775 mill.


$ -8.852 mill.

Employees Shares Outstanding P/E

-


34 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 27.46 %


MRQ Y/Y - %



TCON

$0.97

$-3.9700 -80.36%
This Quarter Q2 of 2024


TCON

$0.97

$-3.9700 -80.36%



Tracon Pharmaceuticals Inc

Tracon Pharmaceuticals Inc stock dropped -80.36% during this current quarter q2 of 2024.


Tracon Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing targeted therapies for cancer and ocular diseases. They primarily collaborate with strategic partners to advance their drug candidates through clinical trials and potentially secure regulatory approval.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 35.750 mill. $ - mill. $ -11.024 mill. 37 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 35.750 mill.


$ - mill.


$ -11.024 mill.

Employees Shares Outstanding P/E

-


37 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



NOTV

$1.72

$-6.7500 -79.69%
This Quarter Q2 of 2024


NOTV

$1.72

$-6.7500 -79.69%



Inotiv Inc

Inotiv Inc shares went down -79.69% during this current quarter q2 of 2024.


Inotiv Inc is a contract research organization (CRO) that provides preclinical and nonclinical research services to the pharmaceutical, biotechnology, and medical device companies. The company offers a range of services including drug discovery, safety assessment, toxicology testing, and analytical services. By assisting clients with their research and development needs, Inotiv aims to contribute to the advancement of medicine and the development of new treatment options.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 44.429 mill. $ 552.744 mill. $ -71.368 mill. 26 mill. - Y/Y -21.41 %
Market Cap. Revenues TTM Net Income TTM

$ 44.429 mill.


$ 552.744 mill.


$ -71.368 mill.

Employees Shares Outstanding P/E

-


26 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -21.41 %


MRQ Y/Y - %



ICU

$3.53

$-12.7700 -78.34%
This Quarter Q2 of 2024


ICU

$3.53

$-12.7700 -78.34%



Seastar Medical Holding Corporation

Seastar Medical Holding Corporation shares went down -78.34% during this current quarter q2 of 2024.


Seastar Medical Holding Corporation*s business model revolves around its operations in the healthcare industry, likely providing medical products or services.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 70.771 mill. $ - mill. $ -42.319 mill. 20 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 70.771 mill.


$ - mill.


$ -42.319 mill.

Employees Shares Outstanding P/E

-


20 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ENDV

$0.0009

$-0.0032 -78.05%
This Quarter Q2 of 2024


ENDV

$0.0009

$-0.0032 -78.05%



Endonovo Therapeutics Inc

Endonovo Therapeutics Inc shares went down -78.05% during this current quarter q2 of 2024.


Endonovo Therapeutics Inc is a biotechnology company focused on the development of non-invasive electroceuticals for regenerative therapies. Their business model centers around the research, development, and commercialization of their innovative technology that stimulates the body*s natural healing process. With a focus on treating inflammatory conditions and diseases, Endonovo aims to provide advanced, non-pharmaceutical solutions for improved patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.216 mill. $ 0.256 mill. $ -4.404 mill. 1,351 mill. - Y/Y -86.13 %
Market Cap. Revenues TTM Net Income TTM

$ 1.216 mill.


$ 0.256 mill.


$ -4.404 mill.

Employees Shares Outstanding P/E

-


1,351 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -86.13 %


MRQ Y/Y - %



AFIB

$0.0425

$-0.1442 -77.24%
This Quarter Q2 of 2024


AFIB

$0.0425

$-0.1442 -77.24%



Acutus Medical Inc

Acutus Medical Inc stock dropped -77.24% during this current quarter q2 of 2024.


Acutus Medical Inc is a medical technology company that develops and commercializes products for the diagnosis and treatment of cardiac arrhythmias. Their business model focuses on producing innovative and advanced medical devices, such as 3D imaging and mapping systems, to help physicians accurately identify and treat irregular heart rhythms.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.262 mill. $ 47.447 mill. $ -66.968 mill. 30 mill. - Y/Y -28.78 %
Market Cap. Revenues TTM Net Income TTM

$ 1.262 mill.


$ 47.447 mill.


$ -66.968 mill.

Employees Shares Outstanding P/E

-


30 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -28.78 %


MRQ Y/Y - %



AONC

$1.32

$-4.3800 -76.84%
This Quarter Q2 of 2024


AONC

$1.32

$-4.3800 -76.84%



American Oncology Network Inc

American Oncology Network Inc shares dropped -76.84% during this current quarter q2 of 2024.


American Oncology Network Inc is a healthcare services company that operates as a physician-led organization, providing comprehensive, community-based oncology care across the United States. They partner with oncologists, hospitals, and practices to deliver high-quality, value-based cancer care while focusing on patient-centric solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 9.937 mill. $ 1,643.524 mill. $ -88.290 mill. 8 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 9.937 mill.


$ 1,643.524 mill.


$ -88.290 mill.

Employees Shares Outstanding P/E

-


8 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ATXI

$3.4

$-11.0000 -76.39%
This Quarter Q2 of 2024


ATXI

$3.4

$-11.0000 -76.39%



Avenue Therapeutics Inc

Avenue Therapeutics Inc stock declined -76.39% during this current quarter q2 of 2024.


Avenue Therapeutics Inc is a pharmaceutical company that focuses on the development and commercialization of intravenous (IV) opioids for acute pain management. They aim to address the needs of the hospital-based market by providing innovative and effective IV pain medications. Through research, clinical trials, and partnerships with healthcare providers, Avenue Therapeutics Inc strives to improve healthcare outcomes for patients suffering from acute pain conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.025 mill. $ - mill. $ -7.235 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.025 mill.


$ - mill.


$ -7.235 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



TFFP

$1.91

$-5.9800 -75.79%
This Quarter Q2 of 2024


TFFP

$1.91

$-5.9800 -75.79%



Tff Pharmaceuticals Inc

Tff Pharmaceuticals Inc shares went down -75.79% during this current quarter q2 of 2024.


TFF Pharmaceuticals Inc*s business model revolves around developing and commercializing novel drug therapies using its Thin Film Freezing (TFF) technology, which enhances the solubility and stability of drugs for improved delivery and patient outcomes. They collaborate with pharmaceutical and biotechnology companies to enhance their existing drug compounds and expand their market potential through licensing and partnership agreements.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.625 mill. $ 0.970 mill. $ -13.704 mill. 2 mill. - Y/Y 738.32 %
Market Cap. Revenues TTM Net Income TTM

$ 3.625 mill.


$ 0.970 mill.


$ -13.704 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 738.32 %


MRQ Y/Y - %



IMRX

$1.69

$-4.8700 -74.24%
This Quarter Q2 of 2024


IMRX

$1.69

$-4.8700 -74.24%



Immuneering Corporation

Immuneering Corporation shares declined -74.24% during this current quarter q2 of 2024.


Immuneering Corp operates on a business model that harnesses the power of big data in the field of biomedicine. Through their proprietary technologies, they analyze vast amounts of biological data to gain insights into disease mechanisms, drug discovery, and patient care. They leverage their expertise to provide pharmaceutical companies and healthcare organizations with actionable information for accelerating the development of new therapeutics and improving clinical outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 49.636 mill. $ - mill. $ -54.175 mill. 29 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 49.636 mill.


$ - mill.


$ -54.175 mill.

Employees Shares Outstanding P/E

11


29 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CRBU

$1.93

$-5.4900 -73.99%
This Quarter Q2 of 2024


CRBU

$1.93

$-5.4900 -73.99%



Caribou Biosciences Inc

Caribou Biosciences Inc stock went down -73.99% during this current quarter q2 of 2024.


Caribou Biosciences Inc is a biotechnology company that focuses on the development of gene editing technologies. Their business model involves licensing their proprietary CRISPR-Cas9 platform and collaborating with partners to advance research and therapeutic applications in various industries.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 172.355 mill. $ 33.404 mill. $ -115.260 mill. 89 mill. - Y/Y -30.64 %
Market Cap. Revenues TTM Net Income TTM

$ 172.355 mill.


$ 33.404 mill.


$ -115.260 mill.

Employees Shares Outstanding P/E

-


89 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -30.64 %


MRQ Y/Y - %



CMAX

$2.945

$-8.2550 -73.71%
This Quarter Q2 of 2024


CMAX

$2.945

$-8.2550 -73.71%



Caremax Inc

Caremax Inc stock went down -73.71% during this current quarter q2 of 2024.


Caremax Inc operates as a healthcare company providing various services and products. Their business model revolves around offering a wide range of medical and healthcare solutions, including home healthcare, medical equipment, and pharmacy services. They aim to meet the diverse needs of patients, ensuring accessible and quality healthcare options through their integrated model.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11.003 mill. $ 763.529 mill. $ -207.146 mill. 4 mill. - Y/Y 28.02 %
Market Cap. Revenues TTM Net Income TTM

$ 11.003 mill.


$ 763.529 mill.


$ -207.146 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 28.02 %


MRQ Y/Y - %



HUGE

$0.2151

$-0.5949 -73.44%
This Quarter Q2 of 2024


HUGE

$0.2151

$-0.5949 -73.44%



Fsd Pharma Inc

Fsd Pharma Inc shares declined -73.44% during this current quarter q2 of 2024.


Fsd Pharma Inc*s business model is centered around the development and production of pharmaceutical-grade cannabis products. The company aims to leverage its in-house cultivation facility, research and development capabilities, and strategic partnerships to create innovative cannabis-based therapies for various medical conditions. Fsd Pharma focuses on pursuing licensing and acquisition opportunities to expand its presence in the global cannabis market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ 4.556 mill. $ -17.902 mill. - mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ - mill.


$ 4.556 mill.


$ -17.902 mill.

Employees Shares Outstanding P/E

-


- mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MGNX

$4.68

$-12.7500 -73.15%
This Quarter Q2 of 2024


MGNX

$4.68

$-12.7500 -73.15%



Macrogenics Inc

Macrogenics Inc stock went down -73.15% during this current quarter q2 of 2024.


Macrogenics Inc is a biopharmaceutical company that focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer and autoimmune diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 291.520 mill. $ 43.357 mill. $ -23.239 mill. 62 mill. - Y/Y -62.83 %
Market Cap. Revenues TTM Net Income TTM

$ 291.520 mill.


$ 43.357 mill.


$ -23.239 mill.

Employees Shares Outstanding P/E

423


62 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -62.83 %


MRQ Y/Y - %



SPRC

$0.9323

$-2.4477 -72.42%
This Quarter Q2 of 2024


SPRC

$0.9323

$-2.4477 -72.42%



Scisparc Ltd

Scisparc Ltd shares dropped -72.42% during this current quarter q2 of 2024.


Scisparc Ltd operates through a specific business model that focuses on providing innovative technological solutions in a particular industry or market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.331 mill. $ 2.879 mill. $ 5.883 mill. 0 mill. 0.06 Y/Y 113.73 %
Market Cap. Revenues TTM Net Income TTM

$ 0.331 mill.


$ 2.879 mill.


$ 5.883 mill.

Employees Shares Outstanding P/E

-


0 mill.


0.06

Revenue Growth Income Growth

MRQ Y/Y 113.73 %


MRQ Y/Y 126.97 %



TOI

$0.464

$-1.2160 -72.38%
This Quarter Q2 of 2024


TOI

$0.464

$-1.2160 -72.38%



The Oncology Institute Inc

The Oncology Institute Inc shares dropped -72.38% during this current quarter q2 of 2024.


The Oncology Institute Inc is a specialized healthcare provider that operates on a fee-for-service business model. It offers comprehensive oncology services, including diagnosis, treatment, and supportive care to patients with various types of cancer. By focusing on delivering high-quality care and personalized treatment plans, the company aims to improve patients* outcomes and quality of life while maintaining financial stability through their fee-based services.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 34.445 mill. $ 342.713 mill. $ -57.768 mill. 74 mill. - Y/Y 24.25 %
Market Cap. Revenues TTM Net Income TTM

$ 34.445 mill.


$ 342.713 mill.


$ -57.768 mill.

Employees Shares Outstanding P/E

-


74 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 24.25 %


MRQ Y/Y - %



PRFX

$0.5502

$-1.4298 -72.21%
This Quarter Q2 of 2024


PRFX

$0.5502

$-1.4298 -72.21%



Painreform Ltd

Painreform Ltd stock went down -72.21% during this current quarter q2 of 2024.


Painreform Ltd operates under a business model focused on developing and commercializing innovative pharmaceutical solutions for pain management. Their approach involves creating novel drug formulations and delivery systems to improve the efficacy, safety, and patient experience in treating acute and chronic pain.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5.866 mill. $ - mill. $ -8.792 mill. 11 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5.866 mill.


$ - mill.


$ -8.792 mill.

Employees Shares Outstanding P/E

-


11 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



PTPI

$0.4641

$-1.1659 -71.53%
This Quarter Q2 of 2024


PTPI

$0.4641

$-1.1659 -71.53%



Petros Pharmaceuticals inc

Petros Pharmaceuticals Inc shares went down -71.53% during this current quarter q2 of 2024.


Petros Pharmaceuticals Inc is a pharmaceutical company that operates on a business model focused on the research, development, and commercialization of innovative drugs and therapeutics. They strive to bring new solutions to market by leveraging their expertise in various therapeutic areas, ultimately aiming to improve patient outcomes and well-being.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.984 mill. $ 2.735 mill. $ -19.765 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.984 mill.


$ 2.735 mill.


$ -19.765 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VTYX

$2.87

$-7.0500 -71.07%
This Quarter Q2 of 2024


VTYX

$2.87

$-7.0500 -71.07%



Ventyx Biosciences Inc

Ventyx Biosciences Inc stock dropped -71.07% during this current quarter q2 of 2024.


Ventyx Biosciences Inc is a biotechnology company that follows a research and development-focused business model. It aims to develop innovative biopharmaceutical products and therapeutic solutions by leveraging its expertise in various fields such as genetic engineering, drug discovery, and clinical trials. The company seeks to form strategic partnerships and licensing agreements to accelerate the commercialization of its products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 168.987 mill. $ - mill. $ -181.423 mill. 59 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 168.987 mill.


$ - mill.


$ -181.423 mill.

Employees Shares Outstanding P/E

-


59 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



EQ

$0.7855

$-1.8845 -70.58%
This Quarter Q2 of 2024


EQ

$0.7855

$-1.8845 -70.58%



Equillium Inc

Equillium Inc shares went down -70.58% during this current quarter q2 of 2024.


Equillium Inc operates on a business model that focuses on developing and commercializing novel treatments for immune and inflammatory disorders by leveraging their expertise in immunology and translational science. They aim to address unmet medical needs through the discovery and development of therapies targeting specific immune pathways.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 27.397 mill. $ 42.632 mill. $ -8.220 mill. 35 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 27.397 mill.


$ 42.632 mill.


$ -8.220 mill.

Employees Shares Outstanding P/E

18,000


35 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GRI

$0.2588

$-0.6192 -70.52%
This Quarter Q2 of 2024


GRI

$0.2588

$-0.6192 -70.52%



Gri Bio Inc

Gri Bio Inc stock dropped -70.52% during this current quarter q2 of 2024.


Gri Bio Inc*s business model focuses on providing innovative biotechnology solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.068 mill. $ - mill. $ -12.528 mill. 4 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.068 mill.


$ - mill.


$ -12.528 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %




 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com